Muscular Dystrophy News -- ScienceDaily

Muscular Dystrophy News -- ScienceDaily
  • Cause of heart arrhythmia in adult muscular dystrophy clarified
    The cause of heart arrhythmia in myotonic dystrophy was RNA abnormalities in the sodium channel in the heart, clarifying the symptom's mechanism, an international joint research group found. This finding will be helpful in prevention and early intervention of death in this disease, leading to the development of new treatment.
  • Cell insights shed light on how muscle-wasting disease takes hold
    Insights into how our cells control muscle development could aid understanding of muscular dystrophy and other inherited diseases, say scientists.
  • New insights into muscular dystrophy point to potential treatment avenues
    Certain stem cells in our bodies have the potential to turn into either fat or muscle. Experiments in mice suggest prospective drugs that manipulate these cells' fate could make it possible to relieve many of the symptoms of muscular dystrophy.
  • New muscular dystrophy drug target identified
    Muscle cells affected by muscular dystrophy contain high levels of an enzyme that impairs muscle repair, scientists have discovered. This finding provides a new target for potential drug treatments for the disease, which currently has no cure.
  • Origin of heart dysfunctions in myotonic dystrophy identified
    An international team of scientists is lifting the veil on the molecular mechanisms causing heart dysfunctions in myotonic dystrophy, a genetic disease affecting one person in 8,000.
  • Scientists reveal how osteopontin ablation ameliorates muscular dystrophy
    Removing an immunomodulatory protein called osteopontin improves the symptoms of mice with muscular dystrophy by changing the type of macrophages acting on damaged muscle tissue, according to a new paper. The study adds support to the idea that osteopontin inhibitors could be used to treat patients with Duchenne muscular dystrophy.
  • Face- and eye-muscle research sheds new light on Duchenne muscular dystrophy
    Researchers have investigated the biochemical and physiological characteristics of orbicularis oculi, a group of facial muscles that control the eyelids and are selectively spared or involved in different neuromuscular disorders. What they found also helps to explain why another set of muscles -- the extraocular muscles that control the movement of the eye -- are not affected by Duchenne muscular dystrophy, congenital muscular dystrophy, and aging.
  • Decoding sugar molecules offers new key for combating muscular dystrophy
    Scientists have succeeded in decoding a sugar molecule and clarifying a mechanism linked to muscular dystrophy. Their discovery has potential implications for muscular dystrophy treatment.
  • New therapeutic target for spinal muscular atrophy
    Neuroscientists have discovered a specific enzyme that plays a critical role in spinal muscular atrophy, and that suppressing this enzyme's activity, could markedly reduce the disease's severity and improve patients' lifestyles.
  • Teaching stem cells to build muscle
    Researchers have identified pecific ways in which fetal muscle stem cells remodel their environment to support their enhanced capacity for regeneration, which could lead to targets for therapies to improve adult stem cells' ability to replace injured or degenerated muscle.
  • Stem cell gene therapy could be key to treating Duchenne muscular dystrophy
    Scientists have developed a new approach that could eventually be used to treat Duchenne muscular dystrophy. The stem cell gene therapy could be applicable for 60 percent of people with Duchenne, which affects approximately 1 in 5,000 boys in the US and is the most common fatal childhood genetic disease.
  • Robotic arm developed for Duchenne patients
    Researchers have developed the A-Gear: a robotic arm that can support the daily activities of people suffering the muscular disease Duchenne Muscular Dystrophy. They recently put the final touches to the first prototype for a discreet, body-connected support aid that can be worn under the clothing and that can support independent operation of the arm during important daily activities. Duchenne Muscular Dystrophy occurs in approximately 1 in 5000 live born boys. The muscles of Duchenne Muscular Dystrophy patients become weaker during their life. As a result, boys with Duchenne lose the ability to use their arms until, eventually, they are unable to use them at all.
  • Cancer drug shows promise for treating Duchenne muscular dystrophy
    A drug commonly used to treat leukemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
  • Gene-editing technique successfully stops progression of Duchenne muscular dystrophy
    Using a new gene-editing technique, a team of scientists has stopped progression of Duchenne muscular dystrophy in young mice. DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
  • Cancer drug shows promise in reducing toxic genetic material in myotonic dystrophy
    A drug used to treat cancer can neutralize the toxic RNA that causes the prolonged muscle contractions and other symptoms of myotonic dystrophy type 1, the most common form of adult-onset muscular dystrophy, a group of researchers has shown for the first time in cells and in a mouse model.